AI and prostate cancer: Balancing hope and caution

The potential applications of artificial intelligence (AI) are vast and span many fields, including urologic oncology. In this interview, Christopher Weight, MD, MS, discusses the current state and directions of AI and prostate cancer. He provides an overview of a recent validation study of the PathomIQ AI tool for prostate cancer prognosis.¹ The study analyzed whole-slide prostate cancer images from 344 men to determine whether AI-derived risk scores—independent of Gleason score and Decipher gene expression profiling—could predict metastasis. The algorithm segmented slide images into patches, assessing architecture, epithelium, and tumor microenvironment to generate a 0 to 1 risk score. Fifteen of 16 patients who developed metastases were flagged as high risk.